The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study

Trial Profile

The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs Evacetrapib (Primary) ; Atorvastatin; Ezetimibe
  • Indications Hyperlipidaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCENTUATE
  • Sponsors Eli Lilly
  • Most Recent Events

    • 02 Sep 2016 Status changed from completed to discontinued due to program termination.
    • 30 Aug 2016 Status changed from discontinued to completed.
    • 10 Dec 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top